Korro Bio, Inc. (KRRO) Cash Flow Statement
Korro Bio, Inc. (KRRO) generated -$67.9M of operating cash flow over the twelve months to 2026-06-30, spent $317000 on capital expenditure and had free cash flow of -$68.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRROKorro Bio, Inc.Follow KRRO — free
—
Price chart with a free account
- Market cap
- 176.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 34.2 | -45.2 | -76.1 | -60.1 | -78.6 | -67.9 | |
| Capital expenditure | 1.1 | 6.7 | 2.9 | 17.9 | 0.5 | -0.3 | |
| Free cash flow | 33.2 | -51.9 | -79.0 | -78.0 | -79.1 | -68.3 | |
| Stock-based compensation | 3.6 | 10.0 | 21.8 | — | — | — |
USD millions · SEC XBRL
Korro Bio, Inc. — questions
- What is Korro Bio, Inc.'s operating cash flow?
- -$67.9M over the twelve months to 2026-06-30.
- How much does Korro Bio, Inc. spend on capital expenditure?
- $317000 over the twelve months to 2026-06-30.
- What is Korro Bio, Inc.'s free cash flow?
- -$68.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Korro Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.